Cell Impact (CI) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 reached SEK 2.2 million, a 175% increase year-over-year, but full-year sales declined 21% to SEK 37.3 million.

• Operating loss (EBIT) for Q4 was SEK -39.7 million, with a full-year loss of SEK -99.0 million, reflecting continued negative earnings.

• Cost-saving programs implemented in 2023–2024 improved cost control, but order volumes remained below expectations.

• Cash and cash equivalents fell to SEK 20.4 million at year-end and SEK 15.1 million by February 2025, raising concerns about future liquidity.

• The company is positioned for high-volume manufacturing with unique patented technology and a flexible business model.

Financial highlights

• Q4 net sales: SEK 2.2 million (Q4 2023: SEK 0.8 million); full-year: SEK 37.3 million (2023: SEK 47.3 million).

• Q4 operating loss: SEK -39.7 million (Q4 2023: SEK -38.8 million); full-year: SEK -99.0 million (2023: SEK -119.5 million).

• Q4 loss after tax: SEK -38.8 million; full-year: SEK -100.4 million.

• Q4 cash flow from operating activities: SEK -7.9 million; full-year: SEK -62.2 million.

• Q4 impairment and disposals of equipment: SEK -15.9 million.

Outlook and guidance

• Full-year outlook remains unchanged, but continued weak order intake may require additional financing.

• Activity levels remain high with around 70 customer projects in various phases at year-end.

• Market demand is expected to accelerate in coming years, with groundwork laid for larger future orders.